Original Article
Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats

Fen Ai¹, Manhua Chen², Bo Yu¹, Yang Yang¹, Guizhong Xu², Feng Gui¹, Zhenxing Liu¹, Xiangyan Bai¹, Zhen Chen¹

¹Department of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430014, Hubei Province, China; ²Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430014, Hubei Province, China

Received July 28, 2015; Accepted October 28, 2015; Epub November 15, 2015; Published November 30, 2015

Abstract: Objective: The traditional Chinese medicinal puerarin, has long been used to treat cardiovascular diseases, however, the mechanism underlying its effects remain unclear. Here, this study would to investigate the role of puerarin on cardiac angiogenesis and myocardial function induced by myocardial infarction. Methods: Puerarin was treated in rats after left anterior descending coronary artery (LAD) ligation and maintained for 4 weeks (diets containing about 50 mg/kg/day or 100 mg/kg/day). After treatment, cardiac function was evaluated by echocardiography and markers of heart failure. Paraffin sections of the heart tissues were used for isolect in GS-IB4 stain ing. The Mrna and protein expression levels of VEGFA, Ang-1 and Ang-2 were detected by real-time polymerase chain reaction and western blot. Results: Significantly damaged angiogenesis and slightly increase of VEGFA, Ang-1 and Ang-2 were showed after LAD ligation. Impaired angiogenesis and cardiac function were remarkably improved in puerarin treatment rats with great increase of VEGFA, Ang-1 and Ang-2. Conclusion: The above results demonstrated that puerarin could accelerate cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 and Ang-2.

Keywords: Puerarin, cardiac angiogenesis, cardiac function, VEGFA, angiopoietin

Introduction
Coronary heart disease (CHD) is one of the contemporary senile diseases, and also is the important cause of death in the elderly [1]. As the development of coronary artery recanalization such as coronary artery stent, ischemic myocardium of the patients with severe myocardial infarction (MI) obtains a lot of benefits [2]. However, the rate of postoperative restenosis rate is greatly high, which limits wide development of coronary recanalization surgery. In recent years, drug-coated stents and novel anticoagulant drugs are widely used, which has significantly reduced the rate of restenosis after coronary stent, but some foreign large-scale clinical trials show that restenosis rate of drug-coated stent is still around 5% [3, 4]. In addition, with the results of BRAVE-2 and TOSCA-2, it is found that drug-coated stents play slight role in late mortality in patients with MI; showed by COURAGE, there is no difference in advantage for stable angina pectoris patients between drug therapy and drug-coated stents [5-8]. Therefore, it is particularly important to promote the formation of collateral circulation of myocardial ischemia region and angiogenesis in the current strategy of CHD. At this point, therapeutic angiogenesis has become a new target for the treatment of CHD. Chinese traditional drug, puerarin as vasodilation drugs, is isolated from the root of kudzu leguminous plant, are commonly used in the clinic for the treatment of myocardial ischemia, cerebral ischemia, dynamic and retinal vein occlusion [9-12]. However, the function of puerarin on left anterior descending coronary artery (LAD) ligation-induced cardiac damage is still unknown. The vascular endothelial growth factor A (VEGFA), angiopoietin-1 (Ang-1) and angiopoie-
etin-2 (Ang-2) are the most powerful and well-studied molecular factors in cardiac angiogenesis [13-16]. And, whether puerarin achieve the aim of treatment of ischemic diseases by promoting new angiogenesis? However, development of a successful therapeutic strategy requires a detailed understanding of the molecular mechanisms involved in coronary angiogenesis, which must rely on extensive bench studies. Therefore, we establish MI model, from the angle of promoting angiogenesis, to identify function of puerarin on LAD ligation-induced cardiac damage and whether it could improve the levels of proangiogenic factors such as VEGFA, Ang-1 and Ang-2, which would be the critical point in this study.

Materials and methods

Materials

Primary antibody against VEGFA (ab51745) was obtained from Abcam (Cambridge, MA, USA). Primary antibodies against Ang-1 (ab118380) and Ang-2 (ab155106) were purchased from Abcam. GAPDH (#MB001) was got from Bio-world Technology (St. Louis Park, MN, USA). TRIZol (#15596018) was obtained from Life Technologies (Invitrogen, NY, USA). The bicinchoninic acid protein assay kit was bought from Pierce Biotechnology, Inc. (Rockford, IL, USA). Isolectin GS-IB4 staining (I21411) was got from Life Technologies (Invitrogen, NY, USA).

Experimental groups

This study was approved by the ethics committee of the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology (Hubei, China). In the present study, the male Sprague-dawley (SD) rats were divided into five groups: the Sham group without any treatment (Sham); the MI group with LAD ligation (MI); the MI+S group treated with Saline after LAD ligation (MI+S); the MI+L group treated with puerarin at low dose (diets containing about 50 mg/kg/day) after LAD ligation (MI+L); the MI+H group treated with Puerarin at high dose (diets containing about 100 mg/kg/day) after LAD ligation (MI+H).

Left anterior descending coronary artery (LAD) ligation and puerarin treatment

The male SD rats (180-200 mg) were randomized to undergo LAD ligation or Sham surgery. All rats were anaesthesitized with 3% pentobarbital sodium (40 mg/kg) by intraperitoneal injection and 1 ml of 1% lidocaine by local injection. Briefly, thoracotomy was performed via the third left intercostal and then the pericardium was torn open. The LAD was ligated by 6-0 polypropylene. It indicated successful ligation when the anterior wall of the left ventricle became visible blanching and swelling of the left atrium became hypokinesis. In Sham group, the suture was passed through the myocardium beneath but the LAD without ligation. All of the LAD ligation-induced cardiac damage lasted for 4 weeks. For the treatment groups, rats were treated with two doses of puerarin (diets containing about 50 mg/kg/day or 100 mg/kg/day) for 4 weeks after LAD ligation. MI+S group rats were received LAD ligation and normal saline.

Assessments of myocardial function

After 4 weeks treatment, myocardial function was evaluated by an echocardiograph equipped with a 15-MHz probe (Acuson Sequoia™ 512 ultrasound system, Siemens Medical Solution USA, Mountain View, CA, USA). Left ventricular end-systolic interior dimension (LVIDs), left ventricular end-diastolic interior dimension (LVIDd), left ventricle rejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were measured in the present study. In addition, we detected the markers of heart failure including atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in different groups.

Isolectin GS-IB4 staining

The hearts were harvested and arrested in diastole phase. After the processes of fixing, dehydration and embedding, to measure the levels of cardiac angiogenesis in different groups, paraffin sections of the whole heart were used for isolectin GS-IB4 staining according to the manufacturer’s instructions (Invitrogen, NY, USA). Pictures of isolectin GS-IB4 staining were taken under the microscope objective.

Real-time polymerase chain reaction (RT-PCR)

To evaluate the levels of VEGFA, Ang-1 and Ang-2, real-time polymerase chain reaction (RT-PCR) analysis was used to detect the mRNA levels of the above factors. Briefly, total mRNA was extracted from myocardium tissue using TRIZol,
Puerarin improves cardiac angiogenesis and cardiac function

Table 1. Echocardiography results for each group

<table>
<thead>
<tr>
<th></th>
<th>Sham</th>
<th>MI</th>
<th>MI+S</th>
<th>MI+L</th>
<th>MI+H</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVIDs (mm)</td>
<td>5.11±0.45</td>
<td>8.85±0.38</td>
<td>8.67±0.29</td>
<td>5.21±0.14</td>
<td>5.38±0.35</td>
</tr>
<tr>
<td>LVIDd (mm)</td>
<td>7.29±0.50</td>
<td>10.51±0.68</td>
<td>10.37±0.74</td>
<td>8.53±0.46</td>
<td>8.70±0.38</td>
</tr>
<tr>
<td>EF (%)</td>
<td>81.62±2.59</td>
<td>33.28±3.65</td>
<td>33.38±3.98</td>
<td>49.59±4.92</td>
<td>49.32±2.67</td>
</tr>
<tr>
<td>FS (%)</td>
<td>40.52±4.00</td>
<td>21.82±4.84</td>
<td>22.57±3.48</td>
<td>32.64±4.22</td>
<td>32.12±4.20</td>
</tr>
</tbody>
</table>

chloroform, isopropanol and 75% DEPC-ethanol. Synthesized cDNA was performed by using oligo (dT) primers with the Transcriptor First Strand cDNA Synthesis Kit. Selected gene differences were measured by quantitative PCR using SYBR green and normalized against gene expression of GAPDH. The sequences of primers in the present study were showed as follows: ANP: 5'-TTCAGACCTCCTCCGAACTAC-3' and 5'-GCTCAAGGTGTCTATCT-3'; BNP: 5'-AGTTGTTACATCGTGTTGTGGA-3' and 5'-CATCATTTCTCGCTGGGAAGC-3'; VEGFA: 5'-TTGTTCAGAGCGGAGAAAGC-3' and 5'-TTTAACTCGTGCTGGGAAGC-3'; Ang-1: 5'-TGATGAGCAGGTGGGAAAGC-3' and 5'-AGCGTCCTTTGGCTCTGAAAT-3'; Ang-2: 5'-ACGGCTGTGATGATCGAGAT-3' and 5'-GGTCTGGTCCAAAATCTGCTG-3'; GAPDH: 5'-ATGGTGAAAGGTCGGTGTGAA-3' and 5'-TGACTGTGCGTTGAAACTTG-3'.

Western blot

Total protein was extracted from the heart tissue and protein concentration was qualified by bicinchoninic acid protein assay kit. Protein was lysed in radio immunoprecipitation assay lysis buffer and then used for SDS-PAGE electrophoresis. The proteins were subsequently transferred to polyvinylidene fluoride membranes and blocked with 5% nonfat dry milk in Tris-buffered saline with Tween 20 (TBST) at room temperature. Membranes were respectively probed with primary antibodies including VEGFA, Ang-1 Ang-2 and GAPDH overnight. Next day, the membranes were washed with 1XTBST, and respectively incubated with corresponding 2nd antibodies (Cell Signaling Technology, Inc.). Following several washes, each image was captured on film, which was placed in Lumiglo® solution (Cell Signaling Technology, Inc.) for one minute. Following development, the images were placed into an automatic image analyzer (Bio-Rad Laboratories, Hercules, CA, USA) to determine the quantity of the proteins as well as the reference grayscale values. A monoclonal GAPDH antibody was used as a loading control and normalized standard.

Statistical analysis

Values are expressed as the mean ± standard error of the mean (SEM). One-way analysis of variance was used for comparisons following by LSD (equal variances assumed) or Tamhane’s T2 (equal variances not assumed) using SPSS version 13.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered as a statistically significant difference.

Results

Puerarin improves myocardial function of rats in response to LAD ligation

LAD ligation challenge resulted in dilated left ventricular chambers and significant decrease in myocardial function as measured by echocardiographic analyses. Compared with Sham group, the LVIDs increased from 5.11 mm to 8.85 mm, the LVIDd increased from 7.29 mm to 10.51 mm, LVEF decreased from 81.62% to 33.28%, LVFS decreased from 40.52% to 21.82%, indicating that MI rats developed heart failure 4 weeks after LAD ligation challenge (Table 1). Exhilaratingly, the MI+L and MI+H groups displayed smaller ventricular chambers and greater cardiac function than MI group, which were evaluated by increases of LVIDs, LVIDd, LVEF and LVFS compared to MI rats (Table 1). Consistent with the results of echocardiographic analyses, it was found that the markers of heart failure including ANP and BNP were decreased in puerarin treatment groups (Figure 1). The above results indicated that puerarin could improve myocardial function of rats in response to myocardial infarction challenge.

Puerarin improves damaged angiogenesis after LAD ligation challenge

In order to observe whether puerarin play a role on cardiac angiogenesis, we performed isolect in GS-IB4 staining in the present study. Compared to Sham group, significantly fewer capillary number sand smaller capillary areas were showed in the hearts of MI rats. Compensatory increases in the capillary area and capillary number were found in puerarin treat-
Puerarin improves cardiac angiogenesis and cardiac function

Puerarin improves cardiac angiogenesis and cardiac function in response to myocardial infarction stress (Figure 2). These results strongly indicated that puerarin could improve severely damaged coronary angiogenesis in response to LAD ligation.

Puerarin upregulates key proangiogenic factors VEGFA, Ang-1 and Ang-2 in response to LAD ligation stress

VEGFA and its downstream targets Ang-1 and Ang-2 are critical for cardiac angiogenesis in response to ischemic stress. Therefore, we measured the expression levels of these factors in every group to better understand the role of puerarin on cardiac angiogenesis. Consistent with impaired cardiac angiogenesis after stress, the mRNA and protein levels of VEGFA, Ang-1 and Ang-2 were lightly increased in MI and MI+S groups compared to the Sham group. However, remarkably increase of VEGFA, Ang-1 and Ang-2 were showed in MI+L and MI+H groups after LAD ligation challenge (Figure 3). These data suggested that puerarin...
Puerarin improves cardiac angiogenesis and cardiac function

could upregulate key proangiogenic factors VEGFA, Ang-1 and Ang-2 in response to LAD ligation stress.

Discussion

Coronary heart disease is a kind of cardiovascular disease, which is due to stenosis or obstruction of coronary artery (fixitylesions including atherosclerosis, or dynamic lesions such as vasospasm), could induce coronary circulation disorder, and then cause imbalances of myocardial oxygen supply and demand and lead to a lack of myocardial ischemia or necrosis, also known as ischemic heart disease [17, 18]. In spite of remarkably development in the preventive health care, cardiovascular medication and cardiac surgery, the incidence and mortality of coronary heart disease remain very high. Therefore, abnormal myocardial circulation and perfusion in ischemic heart disease play a vital role in the development and/or transition from coronary heart disease to heart failure. It was proved that there was a close relationship between depressed cardiac perfusion and damaged cardiac angiogenesis in the myocardium of ischemic heart disease patients [19-21]. Thus it can be seen improvement of coronary microvasculature and acceleration of cardiac angiogenesis might be an important therapeutic target for the treatment of heart failure induced by ischemic heart disease.

The traditional Chinese medicine, puerarin is a kind of flavonoids, which is extracted from the root of a leguminous plant known as puerarin lobata or the root of dried kudzu vine (puerarinthomsonii) [22]. Since 1992, more and more researchers committed to study the functions of puerarin. With the progress of medicines and health products, puerarin has been developed as injection, capsules, tablets, and eye drops or other agents, which is widely used in clinical application to treat coronary heart disease, arrhythmia, hypertension, retinal vein occlusion, sudden deafness, high cholesterol and high blood glucose and shows remarkable curative effect [23, 24]. However, the specific mechanism of puerarin in treating coronary heart disease is still not very clear. In the pres-
Puerarin improves cardiac angiogenesis and cardiac function

In the present study, it is showed that puerarin could improve myocardial function of rats with myocardial infarction, and the application of puerarin play the protective role on cardiac angiogenesis in response to LAD ligation challenge. More importantly, we demonstrated that puerarin functions as a new mediator in the process of compensatory angiogenesis by upregulating the expressions of key proangiogenic factors VEGFA, Ang-1 and Ang-2 during cardiac stress induced by myocardial infarction.

Establishment of coronary collateral circulation includes the formation of original collateral and the formation of new branch. In recent years, it was confirmed the mRNA levels of VEGF and its receptor was increased significantly in myocardial ischemia and hypoxia, suggesting that VEGF is closely related to the formation coronary collateral circulation. VEGF can specifically act on vascular endothelial cells and promote its mitotic division, which can promote angiogenesis in vitro; and also it can effectively promote the establishment of collateral circulation in animals. Although the existence of spontaneous formation of collateral circulation after myocardial ischemia or infarction, the compensatory enhancement of angiogenesis in response to these pathological stimuli appears to be insufficient, and this insufficiency is one of the critical factors responsible for the transition of the heart to heart failure [25]. Exhilaratingly, our research has given the evidence that puerarin can promote the opening and formation of coronary collateral circulation, form abundant collateral circulation to improve the damaged cardiacangiogenesis, a process of sprouting new capillaries, is an adaptive response to myocardial infarction, and this role may be related to upregulation of VEGFA expression and further promotion of Ang-1 and Ang-2 expression.

In conclusion, we revealed a critical role of puerarin in the responsive cardiac angiogenesis with myocardial infarction, which restrain the transition of the heart to heart failure. These findings in the present study will provide the basic and clinical evidence and value in clinical treatment of coronary heart disease. Nevertheless, after ischemia and hypoxia, it can lead to a series of pathophysiological reactions including the release of inflammatory factors, apoptosis and necrosis of cardiomyocytes, collagen fibers accumulation of myocardial interstitial etc. Therefore, it could be studied whether and how puerarin could inhibit cardiac apoptosis, inflammation response and cardiac remodeling in future, which will further clarify the function and mechanism of puerarin on coronary heart disease and so as to lay the theoretical foundation for clinical treatment of myocardial infarction.

Acknowledgements

The authors would like to thank all members of the Department of Emergency (The Central Hospital of Wuhan, Wuhan, China) for their expert technical assistance and advice. The present study was supported by grants from the Natural Science Foundation of Hubei Province (No. 2012FFA107).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Zhen Chen, Department of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science & Technology, No. 26 Shengli Street, Jiang An District, Wuhan 430014, Hubei Province, PR China. Tel: 027+86-27-82211481; Fax: 0+86-27-82211481; 027+86-27-82211481; E-mail: c_z_s_s_@163.com

References

Puerarin improves cardiac angiogenesis and cardiac function


[23] Liu X, Zhao Y, Gao E, Zhao X, Liu Z and Yu Z. Pharmacokinetic comparisons of puerarin, daidzin and the glucuronide metabolite of puerarin after administration of total flavonoid from Gegen alone and total flavonoid from Ge-
Puerarin improves cardiac angiogenesis and cardiac function

